JP2011520969A - 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用 - Google Patents

二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用 Download PDF

Info

Publication number
JP2011520969A
JP2011520969A JP2011510614A JP2011510614A JP2011520969A JP 2011520969 A JP2011520969 A JP 2011520969A JP 2011510614 A JP2011510614 A JP 2011510614A JP 2011510614 A JP2011510614 A JP 2011510614A JP 2011520969 A JP2011520969 A JP 2011520969A
Authority
JP
Japan
Prior art keywords
compound
alkyl
another embodiment
alkylene
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520969A5 (enExample
Inventor
ジョエル エム． ハリス，
サントシュ フランシス ニーラムカヴィル，
バーナード アール． ニュースタッド，
クレイグ ディー． ボイル，
ホン リュ，
ジンソン ハオ，
アンドリュー スタムフォード，
サミュエル チャッカラマニール，
ウィリアム ジェイ． グリーンリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2011520969A publication Critical patent/JP2011520969A/ja
Publication of JP2011520969A5 publication Critical patent/JP2011520969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011510614A 2008-05-19 2009-05-18 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用 Pending JP2011520969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5431908P 2008-05-19 2008-05-19
US61/054,319 2008-05-19
PCT/US2009/044323 WO2009143049A1 (en) 2008-05-19 2009-05-18 Bicyclic heterocycle derivatives and use thereof as gpr119 modulators

Publications (2)

Publication Number Publication Date
JP2011520969A true JP2011520969A (ja) 2011-07-21
JP2011520969A5 JP2011520969A5 (enExample) 2012-07-05

Family

ID=41120129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510614A Pending JP2011520969A (ja) 2008-05-19 2009-05-18 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用

Country Status (6)

Country Link
US (1) US20110065671A1 (enExample)
EP (1) EP2297117B1 (enExample)
JP (1) JP2011520969A (enExample)
AU (1) AU2009249237A1 (enExample)
CA (1) CA2724426A1 (enExample)
WO (1) WO2009143049A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509034A (ja) * 2013-02-25 2016-03-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
JP2017534591A (ja) * 2014-09-29 2017-11-24 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター
JP2021529200A (ja) * 2018-06-26 2021-10-28 昆薬集団股▲フン▼有限公司Ｋｐｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用
JP2022539256A (ja) * 2019-07-02 2022-09-07 エフェクター・セラピューティクス，インコーポレーテッド ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物
JP2022554411A (ja) * 2019-11-11 2022-12-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド アロステリックｅｇｆｒ阻害剤及びその使用方法
JP2026026048A (ja) * 2024-08-02 2026-02-16 イーライ リリー アンド カンパニー Ｇｉｐ受容体アゴニスト化合物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026241A1 (en) * 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
JP2011528369A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
CA2784830C (en) * 2009-12-18 2018-03-27 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CN104119231A (zh) * 2013-04-27 2014-10-29 重庆华邦制药有限公司 二苯甲胺类化合物的制备方法及中间体
CN103848794B (zh) * 2014-04-01 2016-01-20 扬州大学 靛红酸酐及其衍生物的合成方法
WO2015185531A1 (de) 2014-06-05 2015-12-10 Bayer Cropscience Aktiengesellschaft Bicyclische verbindungen als schädlingsbekämpfungsmittel
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
GB201514489D0 (en) 2015-08-14 2015-09-30 Bergen Teknologioverføring As Hyperphenylalaninemia
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
MX2022005229A (es) * 2019-11-01 2022-06-08 Fmc Corp Un nuevo proceso eficaz para la sintesis de 2-amino-5-cloro-n,3-di metilbenzamida.
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN116444445B (zh) * 2023-04-20 2025-08-29 河北科技大学 一种喹唑啉酮类化合物及其制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503530A (ja) * 1990-02-13 1993-06-10 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル成分を含むアンギオテンシン２拮抗物質
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
JPH07133266A (ja) * 1993-11-09 1995-05-23 Agro Kanesho Co Ltd ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
WO2007033192A1 (en) * 2005-09-12 2007-03-22 Wyeth Salicylate and gentisate salts of a piperazine compound
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008025800A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4849405A (en) 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963526A (en) 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US5264439A (en) * 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
US5642868A (en) 1990-05-02 1997-07-01 The United States Of America As Represented By The Secretary Of The Navy Ceramic material
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5843866A (en) 1994-12-30 1998-12-01 Hampshire Chemical Corp. Pesticidal compositions comprising solutions of polyurea and/or polyurethane
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
EA200800375A1 (ru) 1997-05-14 2008-06-30 Атеродженикс, Инк. Соединения и способы ингибирования экспрессии vcam-1
AU5027299A (en) 1998-07-31 2000-02-28 Novo Nordisk A/S Use of glp-1 and analogues for preventing type ii diabetes
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
DK1140189T3 (da) 1998-12-23 2003-09-15 Searle Llc Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
FR2802817B1 (fr) 1999-12-23 2002-10-11 Centre Nat Rech Scient Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
EP1770159A1 (en) 2000-12-01 2007-04-04 Astellas Pharma Inc. Process for manufacturing a pharmaceutical composition for treating diabetes
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
DE602004017703D1 (de) 2003-02-24 2008-12-24 Arena Pharm Inc Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
KR20060056944A (ko) * 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
WO2006012577A2 (en) 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1904458A1 (de) * 2005-07-04 2008-04-02 Boehringer Ingelheim International GmbH Verfahren zur herstellung von chinazolinonderivaten
AU2007208478A1 (en) 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2008130584A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503530A (ja) * 1990-02-13 1993-06-10 メルク・エンド・カムパニー・インコーポレーテツド 置換ベンジル成分を含むアンギオテンシン２拮抗物質
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
JPH07133266A (ja) * 1993-11-09 1995-05-23 Agro Kanesho Co Ltd ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
US6337332B1 (en) * 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法
WO2007033192A1 (en) * 2005-09-12 2007-03-22 Wyeth Salicylate and gentisate salts of a piperazine compound
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008025800A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016509034A (ja) * 2013-02-25 2016-03-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ２−アミノ−３，４−ジヒドロ−キナゾリン誘導体、およびそのカテプシンｄ阻害剤としての使用
JP2017534591A (ja) * 2014-09-29 2017-11-24 ザ スクリプス リサーチ インスティテュート 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター
US11034691B2 (en) 2014-09-29 2021-06-15 The Scripps Research Institute Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders
JP2021529200A (ja) * 2018-06-26 2021-10-28 昆薬集団股▲フン▼有限公司Ｋｐｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用
JP7258059B2 (ja) 2018-06-26 2023-04-14 昆薬集団股▲フン▼有限公司 ベンズイミダゾール誘導体及びそのｉｄｈ１阻害剤としての応用
JP2022539256A (ja) * 2019-07-02 2022-09-07 エフェクター・セラピューティクス，インコーポレーテッド ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物
JP7595055B2 (ja) 2019-07-02 2024-12-05 エフェクター・セラピューティクス，インコーポレーテッド ｅＩＦ４Ｅ阻害４－オキソ－３，４－ジヒドロピリド［３，４－Ｄ］ピリミジン化合物
JP2022554411A (ja) * 2019-11-11 2022-12-28 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド アロステリックｅｇｆｒ阻害剤及びその使用方法
JP7658965B2 (ja) 2019-11-11 2025-04-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド アロステリックｅｇｆｒ阻害剤及びその使用方法
JP2026026048A (ja) * 2024-08-02 2026-02-16 イーライ リリー アンド カンパニー Ｇｉｐ受容体アゴニスト化合物

Also Published As

Publication number Publication date
WO2009143049A1 (en) 2009-11-26
EP2297117B1 (en) 2012-10-31
US20110065671A1 (en) 2011-03-17
AU2009249237A1 (en) 2009-11-26
CA2724426A1 (en) 2009-11-26
EP2297117A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
EP2297117B1 (en) Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP5568154B2 (ja) Ｇｐｒ１１９の活性のモジュレーターとしての二環式ヘテロ環誘導体およびその使用
US8815876B2 (en) Bicyclic heterocycle derivatives and methods of use thereof
US8318751B2 (en) Pyrimidinone derivatives and methods of use thereof
US8580807B2 (en) Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
US20120232073A1 (en) Fused bicyclic pyrimidine derivatives and methods of use thereof
US20100190687A1 (en) Pyrimidinone derivatives and methods of use thereof
US20110118286A1 (en) Bicyclic heterocycle derivatives and their use as gpcr modulators
US8410122B2 (en) Bicyclic heterocycle derivatives and methods of use thereof
US9301929B2 (en) Substituted biaryl derivatives and methods of use thereof
JP2011528365A (ja) Ｇｐｒ１１９モジュレーターとしての二環式ヘテロ環誘導体およびそれらの使用方法
US9409918B2 (en) Bridged bicyclic piperidine derivatives and methods of use thereof
US8722882B2 (en) Pyrimidine derivatives as GPCR modulators for use in the treatment of obesity and diabetes
EP2503891B1 (en) Pyrimidine ether derivatives and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131210

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20140212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140430